Preview

Медицинский Совет

Расширенный поиск

Современные подходы к наружной терапии чувствительных участков кожи при атопическом дерматите у детей: фокус на топические ингибиторы кальциневрина

https://doi.org/10.21518/2079-701X-2019-17-156-167

Полный текст:

Аннотация

Атопический дерматит представляет собой актуальную проблему для педиатров, дерматологов и аллергологов ввиду высокой распространенности в детской популяции, хронического рецидивирующего течения и сложностей выбора тактики местной терапии. В обзорной статье приводятся данные о распространенности и особенностях клинических проявлений атопического дерматита в различные возрастные периоды. Подробно рассматриваются структурно-функциональные и иммунологические особенности кожного барьера в норме и при данной патологии. Сделаны акценты на проблемах качества жизни, комплаентности и стероидофобии пациентов с атопическим дерматитом. Особое внимание уделено концепции чувствительной кожи, определению этого понятия и локализации чувствительных участков кожи на поверхности тела. Освещены подходы к тактике выбора наружной терапии согласно Европейским рекомендациям по лечению атопического дерматита 2018 г. Представлен современный практический алгоритм назначения местных противовоспалительных препаратов (топические глюкокортикостероиды, топические ингибиторы кальциневрина) с учетом тяжести клинических проявлений заболевания и областей нанесения (участки чувствительной кожи / другие участки тела). Приведены доказательства эффективности и безопасности топических ингибиторов кальциневрина, в частности пимекролимуса, при лечении пациентов с легкой и умеренной степенью тяжести атопического дерматита, особенно в участках чувствительной кожи.

Об авторе

Е. Н. Саверская
Медицинский институт непрерывного образования, Московский государственный университет пищевых производств
Россия

Саверская Елена Николаевна, доктор медицинских наук, профессор кафедры фармации

125080, Москва, Волоколамское шоссе, д. 11



Список литературы

1. Wollenberg A., Barbarot S., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: 10.1111/jdv.14888.

2. Kowalska-Olędzka E. Czarnecka M., Baran A. Comparison of treatment standards in Atopic Dermatitis management across selected geographies prior to emerging targeted therapies onset. J Drug Assess. 2019;10;8(1):122-125. doi: 10.1080/21556660.2019.1619569.

3. Silverberg J.I., Hanifin J.M. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132-1138. doi: 10.1016/j.jaci.2013.08.031.

4. Barbarot S., Auziere S., Gadkari A. et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284-1293. doi: 10.1111/all.13401.

5. Weidinger S., Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122. doi: 10.1016/S0140-6736(15)00149-X.

6. Bieber T., D’Erme A.M., Akdis C.A. et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4S):S58-S64. doi: 10.1016/j.jaci.2017.01.008.

7. Smith A.R., Knaysi G., Wilson J.M., Wisniewski J.A. The skin as a route of allergen exposure: part I. Immune components and mechanisms. Curr Allergy Asthma Rep. 2017;17:6. doi: 10.1007/s11882-017-0674-5.

8. Van Smeden J., Bouwstra J.A. Stratum corneum lipids: their role for the skin barrier function in healthy subjects and atopic dermatitis patients. Curr Probl Dermatol. 2016;49:8–26. doi: 10.1159/000441540.

9. Candi E., Schmidt R., Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6:328–340. doi: 10.1038/nrm1619.

10. Proksch E., Brandner J.M., Jensen J.M. The skin: an indispensable barrier. Exp Dermatol. 2008;17:1063–1072. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19043850.

11. Egawa G., Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int. 2018;67(1):3-11. doi: 10.1016/j.alit.2017.10.002.

12. Czarnowicki T., Krueger J.G., Guttman-Yassky E.J. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. Allergy Clin Immunol. 2017;139(6):17231734. doi: 10.1016/j.jaci.2017.04.004.

13. Lai Y., Gallo R.L. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30:131– 141. doi: 10.1016/j.it.2008.12.003.

14. Nakatsuji T., Gallo R.L. Antimicrobial peptides: old molecules with new ideas. J Invest Dermatol. 2012;132:887–895. doi: 10.1038/jid.2011.387.

15. Kim B.E., Leung D.Y.M. Significance of Skin Barrier Dysfunction in Atopic Dermatitis. Allergy Asthma Immunol Res. 2018;10(3):207-215. doi: 10.4168/aair.2018.10.3.207.

16. Elias P.M., Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Allergy Asthma Rep. 2009;9:265–272. doi: 10.1097/ACI.0b013e32832e7d36.

17. Elias P.M., Hatano Y., Williams M.L. Basis for the barrier abnormality in atopic dermatitis: outsideinside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121:1337–1343. doi: 10.1016/j.jaci.2008.01.022.

18. Busse D., Kudella P., Gruning N.M., Gisselmann G., Stander S., Luger T., Jacobsen F., Steinstra.er L., Paus R., Gkogkolou P., Bohm M., Hatt H., Benecke H. A synthetic sandalwood odorant induces woundhealing processes in human keratinocytes via the olfactory receptor OR2AT4. J Invest Dermatol. 2014;134:2823–2832. doi: 10.1038/jid.2014.273.

19. Tang K.T., Ku K.C., Chen D.Y., Lin C.H., Tsuang B.J., Chen Y.H. Adult atopic dermatitis and exposure to air pollutants-a nationwide population-based study. Ann Allergy Asthma Immunol. 2017;118:351– 355. doi: 10.1016/j.anai.2016.12.005.

20. Knox S.M., Erwin E.A., Mosser-Goldfarb J.L., Scherzer R. Sensitization patterns among patients with atopic dermatitis evaluated in a large tertiary care pediatric center. Ann Allergy Asthma Immunol. 2017;118:645–647. doi: 10.1016/j.anai.2017.03.006.

21. Akdis C.A., Akdis M., Bieber T., Bindslev-Jensen C., Boguniewicz M., Eigenmann P. et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy. 2006;(61):969-87. doi: 10.1016/j.jaci.2006.03.045.

22. Irvine A.D., McLean W.H., Leung D.Y. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315–1327. doi: 10.1056/NEJMra1011040.

23. Flohr C., England K., Radulovic S., McLean W.H., Campbel L.E., Barker J., Perkin M., Lack G. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol. 2010;163:1333–1336. doi: 10.1111/j.1365-2133.2010.10068.x.

24. Cork M.J., Danby S.G., Vasilopoulos Y., Hadgraft J., Lane M.E., Moustafa M., Guy R.H., Macgowan A.L., Tazi-Ahnini R., Ward S.J. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;(129):1892-908. doi: 10.1038/jid.2009.133.

25. Akdis C.A., Akdis M., Bieber T., Bindslev-Jensen C., Boguniewicz M., Eigenmann P. et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy. 2006;(61):969-87. doi: 10.1111/j.1398-9995.2006.01153.x.

26. Furue M., Yamamura K., Kido-Nakahara M., Nakahara T., Fukui Y. Emerging role of interleukin-31 and interleukin31 receptor in pruritus in atopic dermatitis. Allergy. 2018;9730:29-36. doi: 10.1111/all.13239.

27. Leung D.Y.M. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;(62):151-61 doi. 10.2332/allergolint.13-RAI-0564.

28. Frosch P.J., Kligman A.M. A method of apraising the stinging capacity of topically applied substances. J Soc Cosmet Chem. 1977;(28):197–209.

29. Thiers H. Peau sensible. In: Thiers H, editor. Les Cosmetiques [Cosmetics]. 2nd edition. Paris: Masson; 1986:266–268.

30. Berardesca E., Fluhr J.W., Maibach H.I. Sensitive skin syndrome. New York: Taylor & Francis. 2006:281. doi. 10.3109/9781420004601.

31. Misery L. Sensitive skin. Expert Rev Dermatol. 2013;(8):631–637. doi. 10.1586/17469872.2013.856688.

32. Misery L., Myon E., Martin N., Verriere F., Nocera T., Taieb C. Peaux sensibles en France: approche epidemiologique. Ann Dermatol Venereol. 2005;(132):425–429. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15988353.

33. Misery L., Boussetta S., Nocera T., Perez-Cullell N., Taieb C. Sensitive skin in Europe. J Eur Acad Dermatol Venereol. 2009;(23):376–381. doi: 10.1111/j.1468-3083.2008.03037.x.

34. Misery L., Sibaud V., Merial-Kieny C., Taieb C. Sensitive skin in the American population: prevalence, clinical data, and role of the dermatologist. Int J Dermatol. 2011;(50):961–967. doi: 10.1111/j.1365-4632.2011.04884.x.

35. Kamide R., Misery L., Perez-Cullell N., Sibaud V., Taieb C. Sensitive skin evaluation in the Japanese population. J Dermatol. 2013;(40):177– 181. doi: 10.1111/1346-8138.12027.

36. Taieb C., Auges M., Georgescu V., Perez-Cullell N., Misery L. Sensitive skin in Brazil and Russia: an epidemiological and comparative approach. Eur J Dermatol. 2014;(24):372–376. doi: 10.1684/ejd.2014.2367.

37. Misery L., Myon E., Martin N., Consoli S., Nocera T., Taieb C. Sensitive skin: epidemiological approach and impact on quality of life in France. In: Berardesca E., Fluhr J.W., Maibach H.I. (eds). Sensitive Skin Syndrome. New York, NY: Taylor and Francis; 2006;169-180.

38. Loffler H., Dickel H., Kuss O., Diepgen T.L., Effendy I. Characteristics of selfestimated enhanced skin susceptibility. Acta Derm Venereol. 2001;81:343– 346. Available at: https://www.researchgate.net/publication/11559089_Characteristics_of_selfestimated_enhanced_skin_susceptibility.

39. Sparavigna A., Di Pietro A., Setaro M. ‘Healthy skin’: significance and results of an Italian study on healthy population with particular regard to ‘sensitive’ skin. Int J Cosmet Sci. 2005;(27):327– 331. doi: 10.1111/j.1467-2494.2005.00287.x.

40. Farage M.A., Bowtell P., Katsarou A. Selfdiagnosed sensitive skin in women with clinically diagnosed atopic dermatitis. Clin Med Dermatol. 2008;(2):21–28.

41. Willis C.M., Shaw S., De Lacharriere O., Baverel M., Reiche L., Jourdain R., Bastien P., Wilkinson J.D. Sensitive skin: an epidemiological study. Br J Dermatol. 2001;(145):258–263. doi: 10.1046/j.1365-2133.2001.04343.x.

42. Jourdain R., de Lacharriere O., Bastien P., Maibach H.I. Ethnic variations in selfperceived sensitive skin: epidemiological survey. Contact Dermatitis. 2002;(46):162–169. doi: 10.1034/j.1600-0536.2002.460307.x.

43. Farage M.A. How do perceptions of sensitive skin differ at different anatomical sites? An epidemiological study. Clin Exp Dermatol 2009;(34):e521– 530. doi: 10.1111/j.1365-2230.2009.03487.x.

44. Kim Y.R., Cheon H.I., Misery L., Taieb C., Lee Y.W. Sensitive skin in Korean population: an epidemiological approach. Skin Res Technol. 2018;(24):229–234. doi: 10.1111/srt.12418.

45. Misery L., Stander S., Szepietowski J.C., Reich A., Wallengren J., Evers A.W. et al. Definition of sensitive skin: an expert position paper from the special interest group on sensitive skin of the international forum for the study of itch. Acta Derm Venereol. 2017;(97):4–6. doi: 10.2340/00015555-2397.

46. Toth B., Olah A., Szollősi A.G., Biro T. TRP channels in the skin. Br J Pharmacol. 2014;(171):2568– 2581. doi: 10.1111/bph.12569.

47. Stander S., Schneider S.W., Weishaupt C., Luger T.A., Misery L. Putative neuronal mechanisms of sensitive skin. Exp Dermatol. 2009;(18):417–423. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19382311.

48. Saint-Martory C., Sibaud V., Theunis J., Mengeaud V., Lauze C., Schmitt A.M., Misery L. Arguments for neuropathic pain in sensitive skin. Br J Dermatol. 2015;(172):1120–1121. doi: 10.1111/bjd.13466.

49. Buhe V., Vie K., Guere C., Natalizio A., Lheritier C., Le Gall-Ianotto C. et al. Pathophysiological study of sensitive skin. Acta Derm Venereol. 2016;(96):314–318. doi: 10.2340/00015555-2235.

50. Pinto P., Rosado C., Parreirao C., Rodrigues L.M. Is there any barrier impairment in sensitive skin? A quantitative analysis of sensitive skin by mathematical modeling of transepidermal water loss desorption curves. Skin Res. Technol. 2011;(17):181–185. doi: 10.1111/j.1600-0846.2010.00478.x.

51. Richters R., Falcone D., Uzunbajakava N., Verkruysse W., van Erp P., van de Kerkhof P. What is sensitive skin? A systematic literature review of objective measurements. Skin Pharmacol Physiol. 2015;(28):75–83. doi: 10.1159/000363149.

52. Misery L., Jourdan E., Huet F., Brenaut E., Cadars B., Virassamynaik S., Sayag M., Taieb C. Sensitive skin in France: a study on prevalence, relationship with age and skin type and impact on quality of life. J Eur Acad Dermatol Venereol. 2018;(32):791–795. doi: 10.1111/jdv.14837.

53. Misery L., Loser K., Stander S. Sensitive skin. J Eur Acad Dermatol Venereol. 2016;30(1):2–8. doi: 10.1111/jdv.13532.

54. Pereira U., Boulais N., Lebonvallet N., Pennec J.P., Dorange G., Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163(1):70-77. doi: 10.1111/j.1365-2133.2010.09757.x.

55. Kim E.J., Lee D.H., Kim Y.K., Eun H.C., Chung J.H. Adiponectin deficiency contributes to sensitivity in human skin. J Invest Dermatol. 2015;(135):2331– 2334. doi: 10.1038/jid.2015.150.

56. Berardersca E., Farage M.A, Maibach H. Sensitive skin: an overview. Int J Cosmet Sci. 2011;(35):2–8. doi: 10.1111/j.1468-2494.2012.00754.x.

57. Saint-Martory C., Roguedas-Contios A.M., Sibaud V., Degouy A., Schmitt A.M., Misery L. Sensitive skin is not limited to the face. Br J Dermatol. 2008;(158):130– 133. doi: 10.1111/j.1365-2133.2007.08280.x.

58. Slodownik D., Williams J., Lee A., Tate B., Nixon R. Controversies regarding the sensitive skin syndrome. Expert Rev Dermatol. 2007;(2):579–584. doi. 10.1586/17469872.2.5.579.

59. Farage M.A. How do perceptions fo sensitive skin differ at different anatomical sites? An epidemiological study. Clin Exp Dermatol. 2009;(34):521– 530. doi: 10.1111/j.1365-2230.2009.03487.x.

60. Marriott M., Holmes J., Peters L., Cooper K., Rowson M., Basketter D.A. The complex problem of sensitive skin. Contact Dermat. 2005;(53):93– 99. doi: 10.1111/j.0105-1873.2005.00653.x.

61. Farage M.A. The Prevalence of Sensitive Skin. Front. Med. 2019;(6):98. doi: 10.3389/fmed.2019.00098.

62. Misery L., Sibaud V., Ambronati M., Macy G., Boussetta S., Taieb C. Sensitive scalp: does this condition exist? An epidemiological study. Contact Dermatitis. 2008;(58): 234–238. doi: 10.1111/j.1600-0536.2007.01288.x.

63. Farage M.A. Perceptions of sensitive skin of the genital area. Current Probl Dermatol. 2011;(40):142–154. doi: 10.1159/000321066.

64. Snyder A., Farhangian M., Feldman S.R. A review of patient adherence to topical therapies for treatment of atopic dermatitis. Cutis. 2015;(96):397-401. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26761934.

65. Feldman S.R., Vrijens B., Gieler U., Piaserico S., Puig L., van de Kerkhof P. Treatment adherence intervention studies in dermatology and guidance on how to support adherence. Am J Clin Dermatol. 2017;(18):253271. doi: 10.1007/s40257-017-0253-5.

66. Patel N., Feldman S.R. Adherence in atopic dermatitis. Adv Exp Med Biol. 2017;(1027):139-159. doi: 10.1007/978-3-319-64804-0_12.

67. Clark R., Bozkaya D., Levenberg M., Levenberg M., Faulkner S., Smith T.W., Gerber R.A. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2%. J Med Econ. 2018;(21):770-777. doi: 10.1080/13696998.2018.1470520.

68. Shah K.N., Cortina S., Ernst M.M., Kichler J.C. Psoriasis in childhood: effectiveтstrategies to improve treatment adherence. Psoriasis (Auckl). 2015;(5):43-54. doi: 10.2147/PTT.S54090.

69. Furue M., Onozuka D., Takeuchi S., Murota H., Sugaya M., Masuda K. et al. Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale-8. Br J Dermatol. 2015;(172):272275. doi: 10.1111/bjd.13377.

70. Thorneloe R.J, Griffiths C.E.M., Emsley R., Ashcroft D.M., Cordingley L. British Association of Dermatologists Biologic Interventions Register; Psoriasis Stratification to Optimise Relevant Therapy study groups. Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength. J Invest Dermatol. 2018;(138):785-794. doi: 10.1016/j.jid.2017.11.015.

71. Beattie P.E., Lewis-Jones M.S. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol. 2003;(28):549553. doi: 10.1046/j.1365-2230.2003.01357.x.

72. Li A.W., Yin E.S., Antaya R.J. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol. 2017;(153):1036-1042. doi: 10.1001/jamadermatol.2017.2437.

73. Aubert-Wastiaux H., Moret L., Le Rhun A., Fontenoy A.M., Nguyen J.M., Leux C. et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;(165):808-814. doi: 10.1111/j.1365-2133.2011.10449.x.

74. Wollenberg A., Oranje A., Deleuran M., Simon D., Szalai Z., Kunz B. et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;(30):729–747. doi: 10.1111/jdv.13599.

75. Wollenberg A., Frank R., Kroth J., Ruzicka T. Proactive therapy of atopic eczema – an evidencebased concept with a behavioral background. J Dtsch Dermatol Ges. 2009;(7):117–121. doi: 10.1111/j.1610-0387.2008.06772.x.

76. Wollenberg A., Ehmann L.M. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012;(24):253–260. doi: 10.5021/ad.2012.24.3.253.

77. Niedner R. Therapie mit systemischen glukokortikoiden. Hautarzt. 2001;(52):1062–1071. Available at: https://www.aerzteblatt.de/archiv/3703/Glukokortikosteroide-in-derDermatologie-Kontrollierter-Einsatz-erforderlich.

78. Charman C., Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol. 2003;(21):193–200. doi: 10.1016/S0738-081X(02)00368-1.

79. Haeck I.M., Rouwen T.J., Timmer-de Mik L., de BruinWeller M.S., BruijnzeelKoomen C.A. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol. 2011;(64):275–281. doi: 10.1016/j.jaad.2010.01.035.

80. Barnes L., Kaya G., Rollason V. Topical corticosteroidinduced skin atrophy: a comprehensive review. Drug Saf. 2015;(38):493–509. doi: 10.1007/s40264-015-0287-7.

81. Meurer M., Eichenfield L.F., Ho V., Potter P.C., Werfel T., Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. J Dermatolog Treat. 2010;(21):157–166. doi: 10.3109/09546630903410158.

82. Ruzicka T., Bieber T., Schopf E., Rubins A., Dobozy A., Bos J.D., Jablonska S., Ahmed I., ThestrupPedersen K., Daniel F., Finzi A., Reitamo S. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;(337):816–821. doi: 10.1056/NEJM199709183371203.

83. Van Leent E.J., Graber M., Thurston M., Wagenaar A., Spuls P.I., Bos J.D. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;(134):805– 809. doi: 10.1001/archderm.134.7.805.

84. Reitamo S., Wollenberg A., Schopf E., Perrot J.L., Marks R., Ruzicka T. et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;(136):999–1006. doi: 10.1001/archderm.136.8.999.

85. Meurer M., Folster-Holst R., Wozel G., Weidinger G., Junger M., Brautigam M.; CASM-DE-01 study group. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;(205): 271– 277. doi: 10.1159/000065863.

86. Wollenberg A., Reitamo S., Girolomoni G., Lahfa M., Ruzicka T., Healy E., Giannetti A., Bieber T., Vyas J., Deleuran M; European Tacrolimus Ointment Study Group. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;(63):742–750. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18592619.

87. Ho V.C., Gupta A., Kaufmann R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;(142):155–162. doi: https://doi.org/10.1067/mpd.2003.65.

88. Eichenfield L.F., Lucky A.W., Boguniewicz M. et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;(46):495–504. doi: 10.1067/mjd.2002.122187.

89. Cury Martins J., Martins C., Aoki V., Gois A.F., Ishii H.A., da Silva E.M. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;(7):CD009864. doi: 10.1002/14651858.CD009864.pub2.

90. Legendre L., Barnetche T., Mazereeuw-Hautier J., Meyer N., Murrell D., Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and metaanalysis. J Am Acad Dermatol. 2015;(72):992–1002. doi: 10.1016/j.jaad.2015.02.1116.

91. Ring J., Barker J., Behrendt H., Darsow U., Dubertret L., Giannetti A. et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol. 2005;(19):663–671. doi: 10.1111/j.1468-3083.2005.01315.x.

92. Margolis D.J., Hoffstad O., Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007;(214):289–295. doi: 10.1159/000100879.

93. Thaci D., Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol. 2010;(28):52–56. doi: 10.1016/j.clindermatol.2009.04.001.

94. Reda A.M., Elgendi A., Ebraheem A.I., Aldraibi M.S., Qari M.S., Abdulghani M.M.R., Luger T. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30(4):366-373. doi: 10.1080/09546634.2018.1524823.

95. Murrell D.F., Calvieri S., Ortonne J.P., Ho V.C., Weise-Riccardi S., Barbier N., Paul C.F. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;(157):954–959. doi: 10.1111/j.1365-2133.2007.08192.x.

96. Hoeger P.H., Lee K.H., Jautova J. et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol. 2009;(160):415–422. doi: 10.1111/j.1365-2133.2008.08928.x.

97. Sigurgeirsson B., Boznanski A., Todd G., Vertruyen A., Schuttelaar M.L., Zhu X. et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. doi: 10.1542/peds.2014-1990.

98. Queille-Roussel C., Paul C., Duteil L. et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001;(144):507-13. doi: 10.1046/j.1365-2133.2001.04076.x.

99. Grzanka A., Zebracka-Gala J., Rachowska R., Bozek A., Kowalska M., Jarzab J. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol. 2012;(21):184-188. doi: 10.1111/j.1600-0625.2011.01417.x.

100. Jensen J.M., Scherer A., Wanke C., Brautigam M., Bongiovanni S., Letzkus M. et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy. 2012;(67):413-23. doi: 10.1111/j.1398-9995.2011.02747.x.

101. Kaufmann R., Bieber T., Helgesen A.L., Andersen B.L., Luger T., Poulin Y., Al-Hafidh J., Paul C.; multicentre investigator group. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy. 2006;(61):375–381. doi: 10.1111/j.1398-9995.2005.00977.x.

102. Fowler J., Johnson A., Chen M., Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007;(79):65–72. Available at: https://www.mdedge.com/dermatology/article/67468/contactdermatitis/improvement-pruritus-childrenatopicdermatitis-using.

103. Gollnick H., Kaufmann R., Stough D. et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol. 2008;(158):1083–1093. doi: 10.1111/j.1365-2133.2008.08484.x.

104. McKenna S.P., Whalley D., de Prost Y., Staab D., Huels J., Paul C.F., van Assche D. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venerol. 2006;(20):248–254. doi: 10.1111/j.1468-3083.2006.01383.x.

105. Staab D., Kaufmann R., Brautigam M., Wahn U.; CASM981CDE04-Study Group. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents’ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005;(16):527–533. doi: 10.1111/j.1399-3038.2005.00306.x.

106. Kempers S., Boguniewicz M., Carter E., Jarratt M., Pariser D., Stewart D., Stiller M., Tschen E., Chon K., Wisseh S., Abrams B. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;(51):515–525. doi: 10.1016/j.jaad.2004.01.051.

107. Billich A., Aschauer H., Aszodi A., Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;(269):29–35. doi: 10.1016/j.ijpharm.2003.07.013.

108. Weiss H.M., Fresneau M., Moenius T., Stuetz A., Billich A. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos. 2008;(36):1812–1818. doi: 10.1124/dmd.108.021915.

109. Allen B.R., Lakhanpaul M., Morris A., Lateo S., Davies T., Scott G., Cardno M., Ebelin M., Burtin P., Stephenson T. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;(88):969–973. doi: 10.1136/adc.88.11.969.

110. Draelos Z., Nayak A., Pariser D., Shupack J.L., Chon K., Abrams B., Paul C.F. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol. 2005;(53):602–609. doi: 10.1016/j.jaad.2005.06.013.

111. Grassberger M., Steinhoff M., Schneider D., Luger T.A. Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;(13):721–730. doi: 10.1111/j.0906-6705.2004.00269.x.

112. Hoetzenecker W., Meingassner J.G., Ecker R., Stingl G., Stuetz A., Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol. 2004;(122):673-84. doi: 10.1111/j.0022-202X.2004.22324.x.

113. Jensen J.M., Ahrens K., Meingassner J., Scherer A., Brautigam M., Stutz A. et al. Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids. Exp Dermatol. 2011;(20):7838. doi: 10.1111/j.1600-0625.2011.01322.x.

114. Buchau A.S., Schauber J., Hultsch T., Stuetz A., Gallo R.L. Pimecrolimus enhances TLR2/6induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol. 2008;(128):2646-54. doi: 10.1038/jid.2008.135.

115. Lubbe J., Friedlander S.F., Cribier B., Morren M.A., Garcia-Diez A., Gelmetti C. et al; NOBEL (New Online Based ELidel) Study Group. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;(7):121-31. doi: 10.2165/00128071200607020-00005.

116. Wahn U., Bos J.D., Goodfield M., Caputo R., Papp K., Manjra A. et al. Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1):1–8. doi: 10.1542/peds.110.1.e2.


Для цитирования:


Саверская Е.Н. Современные подходы к наружной терапии чувствительных участков кожи при атопическом дерматите у детей: фокус на топические ингибиторы кальциневрина. Медицинский Совет. 2019;(17):156-167. https://doi.org/10.21518/2079-701X-2019-17-156-167

For citation:


Saverskaya E.N. Modern approaches to external therapy of sensitive skin area in atopic dermatitis in children: focus on topical calcineurin inhibitors. Meditsinskiy sovet = Medical Council. 2019;(17):156-167. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-156-167

Просмотров: 142


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)